Abstract
Ophthalmological complications constitute a class effect of treatment with BRAF inhibitors. Encorafenib is a new BRAF inhibitor currently being tested in phase 3 clinical trials for advanced or metastatic melanoma as monotherapy or in combination with the MEK-inhibitor binimetinib. In this study, we present a case of severe bilateral panuveitis and neurosensory hearing loss in an elderly patient treated with encorafenib and binimetinib for metastatic BRAF-mutant melanoma. This constellation of findings is compatible with incomplete Vogt-Koyanagi-Harada (VKH) disease. VKH disease is a rare multisystem disease characterized by granulomatous panuveitis, serous retinal detachments, and neurologic and dermatologic manifestations. In patients with melanoma, its emergence has been correlated to a favorable prognosis of the underlying melanoma by several authors. The patient reported here had a severe panuveitis and bilateral retinal detachments causing permanent visual impairment. She was treated with a long course of systemic corticosteroids, but at the same time, she achieved complete remission of the melanoma lasting for 26 months after permanent encorafenib and binimetinib discontinuation, without further antineoplastic treatment....Continue Reading
References
Mar 1, 1978·Archives of Dermatology·A J Sober, H A Haynes
Jan 1, 1984·Microbiology and Immunology·N Maezawa, A Yano
May 1, 1996·International Immunology·S SugitaK Itoh
Nov 1, 1996·The British Journal of Ophthalmology·K Norose, A Yano
May 5, 2001·American Journal of Ophthalmology·R W ReadM Usui
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Nov 18, 2003·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Sabine AisenbreyRichard Brunner
Feb 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Georgina V LongRichard F Kefford
Jul 19, 2014·American Journal of Ophthalmology·Christina H ChoeRavi K Amaravadi
Oct 1, 2012·Retinal Cases & Brief Reports·Ryan K WongJohn J Huang
Feb 7, 2015·Journal of Immunotherapy·Jason N CrossonSteven Yeh
Sep 22, 2016·The Journal of Dermatology·Takashi AraiRyoji Tsuboi
Feb 7, 2017·Journal of Immunotherapy·Marion BricoutLuc Thomas
May 5, 2017·Clinical Case Reports·Toshihiko Matsuo, Osamu Yamasaki
Oct 14, 2017·CA: a Cancer Journal for Clinicians·Jeffrey E GershenwaldUNKNOWN for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Disc
Citations
Apr 21, 2020·Immunotherapy·T GambichlerL Susok
Oct 2, 2020·European Journal of Ophthalmology·Maria BrambatiElisabetta Miserocchi
Dec 30, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Florentia DimitriouMartin Urner
Apr 19, 2020·Journal of Autoimmunity·Céline AnquetilDavid Saadoun
Apr 1, 2021·Drugs·Blake H FortesLauren A Dalvin
May 18, 2021·Ophthalmology·Camille MettlerBenjamin Terrier